← Back to Search


BDTX-4933 for Cancer

Phase 1
Research Sponsored by Black Diamond Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed recurrent/advanced (unresectable) or metastatic solid tumors or histiocytic neoplasms with documented RAS or BRAF mutations
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 1 year
Awards & highlights

Study Summary

This trial studies a new oral medicine to treat certain advanced and metastatic cancers in adults. It looks at how safe and effective the medicine is.

Who is the study for?
Adults with recurrent advanced/metastatic cancers that have specific mutations in the BRAF, KRAS (excluding G12C), or NRAS genes. This includes certain types of lung cancer, melanoma, thyroid cancer, colorectal cancer and other solid tumors. Participants must have tried standard treatments without success and should not be pregnant or breastfeeding.Check my eligibility
What is being tested?
BDTX-4933 is being tested for its safety and effectiveness against various cancers with specific genetic mutations. Patients will take this oral medication in cycles of 28 days to see if it can control their cancer growth.See study design
What are the potential side effects?
Potential side effects are not detailed here but may include typical reactions to anticancer medications such as nausea, fatigue, blood count changes, liver function alterations and possibly others depending on individual patient factors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My cancer is advanced, cannot be surgically removed, and has RAS or BRAF mutations.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Escalation: Incidence of dose-limiting toxicities (DLTs) to estimate the preliminary RP2D and/or MTD of BDTX-4933
Dose Expansion: Duration of response (DOR)
Dose Expansion: Objective response rate (ORR) including extracranial and intracranial
+2 more
Secondary outcome measures
Dose Escalation/Expansion: Area under the plasma drug concentration-time curve (AUC) of BDTX-4933 and its metabolite
Dose Escalation/Expansion: Half-life (t1/2) of BDTX-4933 and its metabolite
Dose Escalation/Expansion: Incidence and severity of treatment-emergent adverse events (TEAEs)
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 1 Dose ExpansionExperimental Treatment1 Intervention
BDTX-4933 will be administered at the RP2D.
Group II: Phase 1 Dose EscalationExperimental Treatment1 Intervention
BDTX-4933 will be administered at escalating dose levels until the maximum tolerated dose (MTD) is reached and the preliminary recommended Phase 2 dose (RP2D) is determined.

Find a Location

Who is running the clinical trial?

Black Diamond Therapeutics, Inc.Lead Sponsor
2 Previous Clinical Trials
291 Total Patients Enrolled

Media Library

BDTX-4933 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05786924 — Phase 1
Lung Cancer Research Study Groups: Phase 1 Dose Escalation, Phase 1 Dose Expansion
Lung Cancer Clinical Trial 2023: BDTX-4933 Highlights & Side Effects. Trial Name: NCT05786924 — Phase 1
BDTX-4933 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05786924 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial currently admit participants?

"Affirmative. According to the clinicaltrials.gov database, this therapeutic trial is currently recruiting participants and was first made public on April 18th 2023. The study requires 140 people from two separate medical sites with an update having been posted as recently as April 24th 2023."

Answered by AI

Has the FDA sanctioned Phase 1 Dose Expansion?

"Due to the limited data collected during Phase 1 trials, our team at Power assigned a score of 1 for Dose Expansion's safety and effectiveness."

Answered by AI

What is the highest capacity of participants in this medical experiment?

"Affirmative. Clinicaltrials.gov lists this trial as actively recruiting, beginning April 18th 2023 and edited last on the 24th of that same month. 140 individuals will be accepted between two distinct sites for this study's duration."

Answered by AI
~67 spots leftby Jun 2026